Idexx Laboratories (IDXX) Stock Statistics & Valuation Metrics

Idexx Laboratories has a market cap or net worth of $51.69B. The enterprise value is $52.74B.

Idexx Laboratories has 79,624,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Idexx Laboratories’s return on equity (ROE) is 0.66 and return on invested capital (ROIC) is 40.27%.

The current PE Ratio of Idexx Laboratories is 49.6. Idexx Laboratories’s PEG ratio is 2.30.

In the last 12 months, Idexx Laboratories had revenue of 4.30B and earned 1.06B in profits. Earnings per share was 13.17.

In the last 12 months, operating cash flow was 1.18B and capital expenditures -124.68M, giving a free cash flow of 1.05B billion.

Idexx Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―

Idexx Laboratories upcoming earnings date is May 6, 2026, Before Open (Confirmed).

Idexx Laboratories as a current ratio of 1.17, with Debt / Equity ratio of 67.10%

In the past 12 months, Idexx Laboratories has paid 264.73M in taxes.

Idexx Laboratories EV to EBITDA ratio is 37.50, with an EV/FCF ratio of 52.29.

Idexx Laboratories has $180.07M in cash and marketable securities with $1.08B in debt, giving a net cash position of -$897.14M billion.

Gross margin is 61.80%, with operating margin of 31.60%, and net profit margin of 24.62%.

The average price target for Idexx Laboratories is $778.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy